Effect of NMDA, a Specific Agonist to NMDA Receptor Complex, on Rat Hippocampus
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605535272 | ||
| 003 | CHVBK | ||
| 005 | 20210128100846.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10517-015-3053-z |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10517-015-3053-z | ||
| 245 | 0 | 0 | |a Effect of NMDA, a Specific Agonist to NMDA Receptor Complex, on Rat Hippocampus |h [Elektronische Daten] |c [V. Motin, V. Yasnetsov] |
| 520 | 3 | |a Removal of Mg2+ ions from perfusion medium provoked epileptiform activity in CA1 field of surviving rat hippocampal slices manifested in generation of extra population spikes. MK-801 (100 μM), a specific non-competitive antagonist to NMDA-receptor complex, prevented this effect. NMDA (20 μM), the specific agonist to this complex, produced no significant effect on the orthodromic population spikes, but when applied at concentrations of 30 or 40 μM, it inhibited them partially (by 21-28%) or almost completely (by 98-99%), correspondingly. Thus, depending on concentration, NMDA can inhibit the synaptic transmission in Schaffer collaterals-hippocampal CA1 pyramidal neurons axis without triggering the epileptiform activity. D-AP5 (50 μM), a competitive antagonist to NMDA-receptor complex, completely prevented the inhibitory effect of NMDA (40 μM). While MK-801 (100 μM) almost completely prevented the inhibitory effect of NMDA, it did not eliminate it when applied after the agonist. Thus, MK-801 can prevent the inhibitory action of NMDA on synaptic transmission in Schaffer collaterals-hippocampal CA1 pyramidal neurons axis via blocking the channel of NMDA-receptor complex, while NMDA exerts its effect only via activation of NMDA receptors. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a hippocampal CA1 field |2 nationallicence | |
| 690 | 7 | |a N-methyl-D-aspartate |2 nationallicence | |
| 690 | 7 | |a NMDA-receptor complex |2 nationallicence | |
| 690 | 7 | |a epileptiform Activity |2 nationallicence | |
| 700 | 1 | |a Motin |D V. |u P. K. Anokhin Research Institute of Normal Physiology, Russian Academy of Medical Sciences, Moscow, Russia |4 aut | |
| 700 | 1 | |a Yasnetsov |D V. |u All-Russian Research Center for Safety of Bioactive Compounds, Staraya Kupavna, Moscow Region, Russia |4 aut | |
| 773 | 0 | |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 159/6(2015-10-01), 704-707 |x 0007-4888 |q 159:6<704 |1 2015 |2 159 |o 10517 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10517-015-3053-z |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10517-015-3053-z |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Motin |D V. |u P. K. Anokhin Research Institute of Normal Physiology, Russian Academy of Medical Sciences, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yasnetsov |D V. |u All-Russian Research Center for Safety of Bioactive Compounds, Staraya Kupavna, Moscow Region, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 159/6(2015-10-01), 704-707 |x 0007-4888 |q 159:6<704 |1 2015 |2 159 |o 10517 | ||